Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Bretuximab vedotin plus re-induction chemotherapy for CD30+ R/R AML

Amir Fathi • 3 Dec 2018
ASH 2018
Acute Myeloid Leukemia Leukemia Antibodies Brentuximab vedotin

Bretuximab vedotin plus re-induction chemotherapy is under investigation for the treatment of CD30+ relapsed/refractory acute myeloid leukemia (AML). Amir Fathi, MD, MPH, of the Massachusetts General Hospital, Boston, MA, discusses the results of this Phase I study (NCT01830777), highlighting tolerability, safety and response data. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Amir Fathi

1:17
Venetoclax plus azacitidine vs intensive chemotherapy induction in fit patients with AML
Amir Fathi • 21 Nov 2023
2:04
Hot topics in the AML space: menin inhibitors
Amir Fathi • 21 Nov 2023
1:44
Improving maintenance therapy in AML: exploring the role of IDH inhibitors
Amir Fathi • 21 Nov 2023
1:12
Managing adverse risk AML: clinical considerations & future outlooks
Amir Fathi • 21 Nov 2023

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals